Testing a person’s blood for a protein called phosphorylated tau could provide a means of large-scale screening for Alzheimer’s disease (AD), according to a new study.
The immunoassay – which has been developed by California biotech ALZpath – focuses on a form of phosphorylated tau known as pTau217 and might be able to detect elevated risk of AD years before symptoms develop.
